Yunsoo Kim

Array ( [id] => 17443823 [patent_doc_number] => 20220064328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => FORMULATION OF NANOANTIBODY BASED DRUGS AND A METHOD FOR TREATING THROMBOTIC THROMBOCYTOPENIC PURPURA BY INHALATION [patent_app_type] => utility [patent_app_number] => 17/464789 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4622 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290848 [patent_doc_number] => 20210386687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAME [patent_app_type] => utility [patent_app_number] => 17/460979 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17460979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770909 [patent_doc_number] => 20230365713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => SIALYLATED GLYCOPROTEINS [patent_app_type] => utility [patent_app_number] => 18/022069 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18022069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520532 [patent_doc_number] => 20220106381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => CD154 PEPTIDES AND METHODS OF INHIBITING CD40 INTERACTIONS WITH CD154 [patent_app_type] => utility [patent_app_number] => 17/400880 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412808 [patent_doc_number] => 20220047712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/395358 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29412 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17561768 [patent_doc_number] => 20220125917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => METHODS FOR PREPARING ALUMINUM PRECIPITATE COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES [patent_app_type] => utility [patent_app_number] => 17/393888 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426925 [patent_doc_number] => 20220054633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => NANOPARTICLES, CONTROLLED-RELEASE DOSAGE FORMS, AND METHODS FOR DELIVERING AN IMMUNOTHERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 17/391663 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17391663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227170 [patent_doc_number] => 20210353726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => PHOSPHOSERINE CONTAINING COMPOSITIONS FOR IMMUNE TOLERANCE INDUCTION [patent_app_type] => utility [patent_app_number] => 17/387239 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058995 [patent_doc_number] => 11938189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Compositions and methods for stabilizing protein-containing formulations [patent_app_type] => utility [patent_app_number] => 17/386385 [patent_app_country] => US [patent_app_date] => 2021-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 17079 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655198 [patent_doc_number] => 20220175663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => STABLE LIQUID ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/378025 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530217 [patent_doc_number] => 20230235287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE [patent_app_type] => utility [patent_app_number] => 18/002248 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18002248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511398 [patent_doc_number] => 20230227546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 [patent_app_type] => utility [patent_app_number] => 18/011412 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140241 [patent_doc_number] => 20210308252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/350781 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050934 [patent_doc_number] => 20240092903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ANTIBODY FORMULATION DILUENT [patent_app_type] => utility [patent_app_number] => 18/000851 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548158 [patent_doc_number] => 20220119499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => Method for the reduction of host cell proteins in affinity chromatography [patent_app_type] => utility [patent_app_number] => 17/335680 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570428 [patent_doc_number] => 20240374720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => ANTIBODY FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/928561 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570428 [patent_doc_number] => 20240374720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => ANTIBODY FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/928561 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483689 [patent_doc_number] => 20230210991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => ANTIBODY-CONTAINING FORMULATION [patent_app_type] => utility [patent_app_number] => 17/926313 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483689 [patent_doc_number] => 20230210991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => ANTIBODY-CONTAINING FORMULATION [patent_app_type] => utility [patent_app_number] => 17/926313 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272987 [patent_doc_number] => 20210379185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING [patent_app_type] => utility [patent_app_number] => 17/332521 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332521 [rel_patent_id] =>[rel_patent_doc_number] =>)